EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
Target drugs acting via the HIF/VEGF pathway show a steady-state clinical effect in treating patients with metastatic renal cell carcinoma (RCC). However, to continue therapy in patients with developing resistance in the prolonged use of tyrosine kinase inhibitors remained unsolved, which brought ab...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/279 |